Is crizotinib effective against bone metastasis?

Crizotinib is a competitive small molecule inhibitor of receptor tyrosine kinases (RTK) C-Met, ALK and ROS1ATP. Crizotinib has positive effects in the treatment of cancer and also has positive effects on patients with bone metastases.

Researchers conducted the study in a study of 343patients with metastatic ALK+ non-small cell lung cancer. Crizotinib treatment, 172 patients received crizotinib treatment, 171 patients received chemotherapy, and the results of each group were compared. Among patients with ALK+non-small cell lung cancer(NSCLC), patients who received crizotinib had 10.9 months, and for people who received chemotherapy, the median time without tumor growth or spread was 7 months.

In a study of 50 patients, researchers looked at the effectiveness of crizotinib in ROS1+non-small cell lung cancer(NSCLC)efficacy in patients with ROS1+non-small cell lung cancer is rarer than ALK+, occurring in only 1% of patients with non-small cell lung cancer. The percentage of people taking crizotinib who experienced a tumor response (such as tumor shrinkage) was 66% (overall response response rate (ORR), one patient had a complete response and 64% (32/50) had a partial response.

Crizotinib in26nameALKpositive anaplastic large cell lymphoma(ALCL)Studies were conducted in patients who had relapsed or failed to respond to prior therapy and ranged in age from 3 years to 20 years, with 11 years being the most common age. Overall, 88% of patients responded, with 21 patients (81%) having a complete response and 2 patients (8%) having a partial response. Of 23 patients who responded, 13 patients (57%) maintained response at 3 months and 9 patients (39%) maintained a response at 6 months, and 5(22%) patients maintained a response at 12 months. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.

xa0